PL2041282T3 - Kwasy nukleinowe wiążące sdf-i - Google Patents
Kwasy nukleinowe wiążące sdf-iInfo
- Publication number
- PL2041282T3 PL2041282T3 PL07786160T PL07786160T PL2041282T3 PL 2041282 T3 PL2041282 T3 PL 2041282T3 PL 07786160 T PL07786160 T PL 07786160T PL 07786160 T PL07786160 T PL 07786160T PL 2041282 T3 PL2041282 T3 PL 2041282T3
- Authority
- PL
- Poland
- Prior art keywords
- sdf
- nucleic acids
- binding nucleic
- binding
- acids
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014957 | 2006-07-18 | ||
| EP07786160.7A EP2041282B1 (en) | 2006-07-18 | 2007-07-18 | Sdf-i binding nucleic acids |
| PCT/EP2007/006387 WO2008009437A2 (en) | 2006-07-18 | 2007-07-18 | Sdf-i binding nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2041282T3 true PL2041282T3 (pl) | 2018-07-31 |
Family
ID=38947372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07786160T PL2041282T3 (pl) | 2006-07-18 | 2007-07-18 | Kwasy nukleinowe wiążące sdf-i |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8314223B2 (enExample) |
| EP (1) | EP2041282B1 (enExample) |
| JP (1) | JP5380287B2 (enExample) |
| KR (2) | KR101466931B1 (enExample) |
| CN (2) | CN103555725B (enExample) |
| AR (1) | AR061929A1 (enExample) |
| AU (1) | AU2007276435C1 (enExample) |
| BR (1) | BRPI0714844B8 (enExample) |
| CA (1) | CA2658267C (enExample) |
| DK (1) | DK2041282T3 (enExample) |
| ES (1) | ES2663404T3 (enExample) |
| MX (1) | MX2009000656A (enExample) |
| PL (1) | PL2041282T3 (enExample) |
| PT (1) | PT2041282T (enExample) |
| RU (1) | RU2590709C2 (enExample) |
| WO (1) | WO2008009437A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
| KR101589442B1 (ko) * | 2007-08-06 | 2016-02-01 | 녹손 파르마 아게 | 에스디에프-1 결합형 핵산 및 이의 용도 |
| JP5463621B2 (ja) * | 2008-02-27 | 2014-04-09 | ソニー株式会社 | 標的物質の定量方法 |
| US8710021B2 (en) * | 2008-06-11 | 2014-04-29 | Bionucleon S.R.L. | Inhibition of HRP-3 using modified oligonucleotides |
| TWI578992B (zh) * | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
| AU2011300818B2 (en) * | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
| EP2633053A1 (en) * | 2010-10-29 | 2013-09-04 | Noxxon Pharma AG | Use of hepcidin binding nucleic acids for depletion of hepcidin from the body |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| WO2016096640A2 (en) * | 2014-12-17 | 2016-06-23 | Cancer Research Technology Ltd | Anti-cxcl12 antibody molecules and their uses |
| US11371045B2 (en) * | 2016-04-15 | 2022-06-28 | Noxxon Pharma Ag | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| US11221270B2 (en) * | 2018-02-27 | 2022-01-11 | Kevan M Evans | Method and apparatus for detecting slow leaks |
| WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
| CN115997122A (zh) | 2020-06-26 | 2023-04-21 | 拉夸里亚创药株式会社 | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 |
| WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| IE920562A1 (en) * | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| EP1072273B1 (en) * | 1998-03-24 | 2006-07-26 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| US6670149B1 (en) * | 1999-03-01 | 2003-12-30 | Millennium Pharmaceuticals, Inc. | TWIK-5 potassium channel nucleic acids and uses therefor |
| US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| EP1133988A1 (en) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| EP1717583A3 (en) * | 2001-06-07 | 2007-10-10 | ChemoCentryx Inc | Cell migration assay |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| GB0225833D0 (en) | 2002-11-06 | 2002-12-11 | Univ Leeds | Nucleic acid ligands and uses therefor |
| ES2729826T3 (es) | 2004-09-23 | 2019-11-06 | Arc Medical Devices Inc | Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato |
| DE502005009920D1 (de) * | 2004-11-29 | 2010-08-26 | Noxxon Pharma Ag | Vasopressin bindende l-nukleinsäure |
| BRPI0707446A2 (pt) | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| JP5296701B2 (ja) | 2006-11-30 | 2013-09-25 | ユニバーシティ オブ バージニア パテント ファウンデーション | 線維性疾患および線維増殖性疾患を処置および診断するための方法 |
| KR101589442B1 (ko) | 2007-08-06 | 2016-02-01 | 녹손 파르마 아게 | 에스디에프-1 결합형 핵산 및 이의 용도 |
| US20090274687A1 (en) | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
-
2007
- 2007-07-18 WO PCT/EP2007/006387 patent/WO2008009437A2/en not_active Ceased
- 2007-07-18 PL PL07786160T patent/PL2041282T3/pl unknown
- 2007-07-18 EP EP07786160.7A patent/EP2041282B1/en active Active
- 2007-07-18 PT PT77861607T patent/PT2041282T/pt unknown
- 2007-07-18 DK DK07786160.7T patent/DK2041282T3/en active
- 2007-07-18 MX MX2009000656A patent/MX2009000656A/es active IP Right Grant
- 2007-07-18 CA CA2658267A patent/CA2658267C/en active Active
- 2007-07-18 AR ARP070103212A patent/AR061929A1/es active IP Right Grant
- 2007-07-18 AU AU2007276435A patent/AU2007276435C1/en active Active
- 2007-07-18 RU RU2009105494/10A patent/RU2590709C2/ru active
- 2007-07-18 ES ES07786160.7T patent/ES2663404T3/es active Active
- 2007-07-18 JP JP2009519869A patent/JP5380287B2/ja active Active
- 2007-07-18 BR BRPI0714844A patent/BRPI0714844B8/pt active IP Right Grant
- 2007-07-18 CN CN201310486348.1A patent/CN103555725B/zh active Active
- 2007-07-18 CN CN2007800305243A patent/CN101506364B/zh active Active
- 2007-07-18 KR KR1020097000923A patent/KR101466931B1/ko active Active
- 2007-07-18 KR KR1020137020754A patent/KR101561652B1/ko active Active
-
2009
- 2009-01-18 US US12/374,311 patent/US8314223B2/en active Active
-
2012
- 2012-10-13 US US13/651,385 patent/US9035038B2/en active Active
-
2015
- 2015-05-06 US US14/705,809 patent/US9822369B2/en active Active
-
2017
- 2017-11-20 US US15/818,618 patent/US20180163207A1/en not_active Abandoned
-
2020
- 2020-11-09 US US17/092,390 patent/US20210139909A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2041282T3 (pl) | Kwasy nukleinowe wiążące sdf-i | |
| HRP20181833T1 (hr) | Ekspresija proteina iz više nukleinskih kiselina | |
| GB0706243D0 (en) | Modified nucleic acids | |
| IL186085A0 (en) | Ghrelin binding nucleic acids | |
| GB2449354B (en) | Binding protein | |
| IL176133A0 (en) | Stapler | |
| IL195066A0 (en) | Cancer-related nucleic acids | |
| EP1910534A4 (en) | DNA-BINDING PROTEIN-POLYMERASE CHIMERAE | |
| EP2077326A4 (en) | NOVEL NUCLEIC ACID | |
| GB0611116D0 (en) | Proteins | |
| GB0603160D0 (en) | Nucleic acid | |
| GB0612542D0 (en) | Combinations comprising staurosporines | |
| EP2050543A4 (en) | CLAMP MACHINE | |
| GB0601976D0 (en) | Proteins | |
| GB0620735D0 (en) | Proteins | |
| GB2453894B (en) | Binding assembly | |
| TWI371353B (en) | Stapler | |
| GB0520523D0 (en) | Object binding | |
| GB0605471D0 (en) | Stapler | |
| GB0605672D0 (en) | Indirect heating | |
| GB0612443D0 (en) | Protein | |
| GB0612623D0 (en) | Proteins | |
| GB0614682D0 (en) | Proteins | |
| GB0620304D0 (en) | Protein | |
| HU0600159D0 (en) | Kvantitative pcr |